PET/CT imaging in cancer: current applications and future directions

Farwell, Michael D.; Pryma, Daniel A.; Mankoff, David A.

doi:10.1002/cncr.28860

Cited by 230Medical Imaging Techniques and ApplicationsRadiopharmaceutical Chemistry and ApplicationsCancer, Hypoxia, and Metabolism

PET/CT imaging in cancer: current applications and future directions

Open access

Farwell, Michael D., Pryma, Daniel A., Mankoff, David A.·2014·Cancer

DOI 10.1002/cncr.28860

Open this paper in CoChat — free account Open PDF

Abstract

Positron emission tomography (PET) is a radiotracer imaging method that yields quantitative images of regional in vivo biology and biochemistry. PET, now used in conjunction with computed tomography (CT) in PET/CT devices, has had its greatest impact to date on cancer and is now an important part of oncologic clinical practice and translational cancer research. In this review of current applications and future directions for PET/CT in cancer, the authors first highlight the basic principles of PET followed by a discussion of the biochemistry and current clinical applications of the most commonly used PET imaging agent, 18 F‐fluorodeoxyglucose (FDG). Then, emerging methods for PET imaging of other biologic processes relevant to cancer are reviewed, including cellular proliferation, tumor hypoxia, apoptosis, amino acid and cell membrane metabolism, and imaging of tumor receptors and other tumor‐specific gene products. The focus of the review is on methods in current clinical practice as well as those that have been translated to patients and are currently in clinical trials. Cancer 2014;120:3433–3445. © 2014 American Cancer Society.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cncr.28860

Cites

137 of 137 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glucose uptake by cancer cells has been successfully exploited via FDG-PET imaging to stage cancers and assess response to therapy.
“Despite challenges associated with targeting glucose metabolism directly, glucose uptake by cancer cells has been successfully exploited in patients through the use of the fluoro-deoxyglucose positron-emission-tomography (FDG-PET) imaging to stage cancers and assess response to therapy (d’Amico, 2015; Farwell et al., 2014; Zhu et al., 2011).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Farwell et al., 2014

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Part of this paper’s reference list could not be split into single entries.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works
THE [ <sup>14</sup> C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT <sup>1</sup>
Sokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000 · see citing works
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777 · see citing works
Untitled work
(1989) · PubMed · Cited by 3,343 · see citing works
Cancer and Radiation Therapy: Current Advances and Future Directions
Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.3635 · Cited by 2,927 · see citing works
Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method
Phelps, M. E., Huang, S. C., Hoffman, E. J., Selin, C. E., Sokoloff, L., & Kuhl, D. E. (1979) · Annals of Neurology · doi:10.1002/ana.410060502 · Cited by 2,417 · see citing works
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240 · see citing works
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations
Young, H. E., Baum, R. P., Cremerius, U., Herholz, K., Hoekstra, O. S., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,716 · see citing works
Imaging proliferation in vivo with [F-18]FLT and positron emission tomography
Shields, A. F., Grierson, J. R., Dohmen, B. M., Machulla, H.-J., Stayanoff, J. C., Lawhorn‐Crews, J. M., Obradovich, J. E., Muzik, O., & Mangner, T. J. (1998) · Nature Medicine · doi:10.1038/3337 · Cited by 1,204 · see citing works
Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography.
(1992) · PubMed Central · doi:10.2967/jnumed.120.251744a · Cited by 1,172 · see citing works
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study
Nordsmark, M., Bentzen, S. M., Rudat, V., Brizel, D., Lartigau, E., Stadler, P., Becker, A., Adam, M., Molls, M., Dunst, J., et al. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.06.038 · Cited by 953 · see citing works
Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
Afshar‐Oromieh, A., Zechmann, C. M., Malcher, A., Eder, M., Eisenhut, M., Linhart, H., Holland‐Letz, T., Hadaschik, B. A., Giesel, F. L., Debus, J., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2525-5 · Cited by 920 · see citing works
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
Afshar‐Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H., Hadaschik, B. A., Holland‐Letz, T., Giesel, F. L., Kratochwil, C., Haufe, S., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2298-2 · Cited by 919 · see citing works
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
Dijkers, E. C. F., Munnink, T. H. O., Kosterink, J. G. W., Brouwers, A. H., Jager, P. L., de Jong, J. R., van Dongen, G. A. M. S., Schroder, C. P., Hooge, M. N. L., & de Vries, E. G. E. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.12 · Cited by 810 · see citing works
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.
Hutchings, M., Loft, A., Hansen, M., Pedersen, L., Buhl, T., Jurlander, J., Buus, S., Keiding, S., d'Amore, F., Boesen, A., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2252 · Cited by 757 · see citing works
Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines
Yanagida, O., Kanai, Y., Chairoungdua, A., Kim, D. K., Segawa, H., Nii, T., Cha, S. H., Matsuo, H., Fukushima, J.-I., Fukasawa, Y., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00384-4 · Cited by 746 · see citing works
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
Shankar, L. K., Hoffman, J. M., Bacharach, S. L., Graham, M. M., Karp, J. S., Lammertsma, A. A., Larson, S. M., Mankoff, D. A., Siegel, B. A., den Abbeele, A. V., et al. (2006) · PubMed · Cited by 677 · see citing works
Self-citation
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Kelloff, G. J., Hoffman, J. M., Johnson, B. E., Scher, H. I., Siegel, B. A., Cheng, E. Y., Cheson, B. D., O’Shaughnessy, J., Guyton, K. Z., Mankoff, D. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2626 · Cited by 672 · see citing works
Self-citation
Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.
Wahl, R., Zasadny, K., Helvie, M., Hutchins, G., Weber, B., & Cody, R. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2101 · Cited by 633 · see citing works
Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning
Robbins, R. J., Wan, Q., Grewal, R. K., Reibke, R., Gönen, M., Strausś, H. W., Tuttle, R. M., Drucker, W. D., & Larson, S. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1534 · Cited by 582 · see citing works
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
Stroobants, S., Goeminne, J., Seegers, M., Dimitrijević, S., Dupont, P., Nuyts, J., Martens, M., van den Borne, B. V. D., Cole, P., Sciot, R., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00073-x · Cited by 555 · see citing works
Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02
Rischin, D., Hicks, R. J., Fisher, R., Binns, D., Corry, J. F., Porceddu, S. V., & Peters, L. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2878 · Cited by 540 · see citing works
Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography
Bos, R., van der Hoeven, J. V. D., van der Wall, E., van der Groep, P., van Diest, P. V., Comans, E., Joshi, U., Semenza, G., Hoekstra, O., Lammertsma, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.379 · Cited by 480 · see citing works
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
Ott, K., Weber, W., Lordick, F., Becker, K., Busch, R. M., Herrmann, K., Wieder, H. A., Fink, U., Schwaiger, M., & Siewert, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7801 · Cited by 463 · see citing works
Anatomy of SUV
Huang, S. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00155-4 · Cited by 458 · see citing works
Expression of glucose transporters in cancers
Szablewski, L. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.12.004 · Cited by 453 · see citing works
Non–Small Cell Lung Cancer: Prospective Comparison of Integrated FDG PET/CT and CT Alone for Preoperative Staging
Shim, S. S., Lee, K. S., Kim, B. T., et al. (2005) · Radiology · doi:10.1148/radiol.2363041310 · Cited by 445 · see citing works
Positron Emission Tomography Using [18F] Fluorodeoxyglucose in Brain Tumors A Powerful Diagnostic and Prognostic Tool
Chiro, G. D. (1987) · Investigative Radiology · doi:10.1097/00004424-198705000-00002 · Cited by 444 · see citing works
Positron emission tomography scanning in the evaluation of hepatocellular carcinoma
Khan, A., Combs, C. S., Brunt, E. M., Lowe, V. J., Wolverson, M., Solomon, H. S., Collins, B. T., & Bisceglie, A. M. D. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80248-2 · Cited by 414 · see citing works
Metabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast Cancer
Mortimer, J. E., Dehdashti, F., Siegel, B. A., Trinkaus, K. M., Katzenellenbogen, J. A., & Welch, M. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2797 · Cited by 410 · see citing works
Positron Emission Tomography Using [18F]-Fluorodeoxy- d -Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy
Smith, I. C., Welch, A. E., Hutcheon, A. W., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1676 · Cited by 409 · see citing works
Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
Buck, A. K., Halter, G., Schirrmeister, H., Kotzerke, J., Wurziger, I., Glatting, G., Mattfeldt, T., Neumaier, B., Reske, S. N., & Hetzel, M. (2003) · PubMed · Cited by 403 · see citing works
Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer
Linden, H. M., Stekhova, S. A., Link, J. M., Gralow, J. R., Livingston, R. B., Ellis, G. K., Pétra, P. H., Peterson, L. M., Schubert, E. K., Dunnwald, L. K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3810 · Cited by 392 · see citing works
Self-citation
Reproducibility of metabolic measurements in malignant tumors using FDG PET.
Weber, W., Ziegler, S. I., Thödtmann, R., Hanauske, A.-R., & Schwaiger, M. (1999) · PubMed · Cited by 390 · see citing works
Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.
Römer, W., Hanauske, A.-R., Ziegler, S. I., Thödtmann, R., Weber, W., Fuchs, C., Enne, W., Herz, M., Nerl, C., Garbrecht, M., et al. (1998) · PubMed · doi:10.1182/blood.v91.12.4464 · Cited by 334 · see citing works
Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man
Beer, A. J., Haubner, R., Sarbia, M., Goebel, M., Luderschmidt, S., Grosu, A., Schnell, O., Niemeyer, M., Kessler, H., Wester, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0266 · Cited by 330 · see citing works
Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography
Bos, R., van der Hoeven, J. J. M., van der Wall, E., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.2.379 · Cited by 329 · see citing works
Imaging of Cell Proliferation: Status and Prospects
Bading, J. R., & Shields, A. F. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.046391 · Cited by 321 · see citing works
Positron Emission Tomography As an Imaging Biomarker
Weber, W. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6068 · Cited by 313 · see citing works
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.
Larson, S. M., Morris, M. J., Guenther, I., Beattie, B., Humm, J. L., Akhurst, T., Finn, R. D., Erdi, Y. E., Pentlow, K. S., Dyke, J., et al. (2004) · PubMed · Cited by 298 · see citing works
Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
Dehdashti, F., Mortimer, J. E., Siegel, B. A., et al. (1995) · PubMed · Cited by 290 · see citing works
Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer
Cho, S. Y., Gage, K. L., Mease, R. C., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.104661 · Cited by 279 · see citing works
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography
Kenny, L. M., Coombes, R. C., Vigushin, D. M., AL-NAHHAS, A. M., Shousha, S., & Aboagye, E. O. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0379-4 · Cited by 273 · see citing works
Brain tumour imaging with PET: a comparison between [ 18 F]fluorodopa and [ 11 C]methionine
Becherer, A., Karanikas, G., Szab�, M., Zettinig, G., Asenbaum, S., Marosi, C., Henk, C. B., Wunderbaldinger, P., Czech, T., Wadsak, W., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1259-1 · Cited by 264 · see citing works
Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues.
Paquet, N., Albert, A., Foidart, J., & Hustinx, R. (2004) · PubMed · Cited by 257 · see citing works
An Interindividual Comparison of O-(2- [18F]Fluoroethyl)-L-Tyrosine (FET)– and L-[Methyl-11C]Methionine (MET)–PET in Patients With Brain Gliomas and Metastases
Grosu, A., Astner, S. T., Riedel, E., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.07.002 · Cited by 254 · see citing works
Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.
Mankoff, D. A., Dunnwald, L. K., Gralow, J. R., Ellis, G. K., Charlop, A. W., Lawton, T. J., Schubert, E. K., Tseng, J. R., & Livingston, R. B. (2002) · PubMed · Cited by 253 · see citing works
Self-citation
Aberrant Glycolytic Metabolism of Cancer Cells: A Remarkable Coordination of Genetic, Transcriptional, Post-translational, and Mutational Events That Lead to a Critical Role for Type II Hexokinase
Mathupala, S. P., Rempel, A., & Pedersen, P. L. (1997) · Journal of Bioenergetics and Biomembranes · doi:10.1023/a:1022494613613 · Cited by 250 · see citing works
The lessons of GIST--PET and PET/CT: a new paradigm for imaging.
den Abbeele, A. D. V. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s2-8 · Cited by 229 · see citing works
Mammalian hexokinases and their abnormal expression in cancer.
Smith, T. (2000) · PubMed · Cited by 223 · see citing works
11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas
Singhal, T., Narayanan, T. K., Jain, V. K., Mukherjee, J., & Mantil, J. (2007) · Molecular Imaging and Biology · doi:10.1007/s11307-007-0115-2 · Cited by 223 · see citing works
Radiosynthesis of 3′-deoxy-3′-[18F]fluorothymidine: [18F]FLT for imaging of cellular proliferation in vivo
Grierson, J. R., & Shields, A. F. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(99)00104-3 · Cited by 214 · see citing works
Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis
Eary, J. F., O’Sullivan, F., Powitan, Y., et al. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0859-5 · Cited by 214 · see citing works
Assessing Tumor Hypoxia in Cervical Cancer by PET with 60Cu-Labeled Diacetyl-Bis(N4-Methylthiosemicarbazone)
Dehdashti, F., Grigsby, P. W., Lewis, J. S., Laforest, R. A., Siegel, B. A., & Welch, M. J. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.048520 · Cited by 212 · see citing works
Correlation between Ki-67 immunohistochemistry and 18F-Fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis
Chalkidou, A., Landau, D., Odell, E. W., Cornelius, V. R., O’Doherty, M. J., & Marsden, P. K. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.001 · Cited by 206 · see citing works
Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors
Su, H. C., Bodenstein, C., Dumont, R. A., Seimbille, Y., Dubinett, S. M., Phelps, M. E., Herschman, H. R., Czernin, J. G., & Weber, W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0368 · Cited by 202 · see citing works
Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.
Mankoff, D. A., Dunnwald, L. K., Gralow, J. R., Ellis, G. K., Schubert, E. K., Tseng, J. R., Lawton, T. J., Linden, H. M., & Livingston, R. B. (2003) · PubMed · Cited by 202 · see citing works
Self-citation
Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG.
Kubota, R., Kubota, K., Yamada, S., et al. (1995) · PubMed · Cited by 196 · see citing works
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer
Morris, M. J., Akhurst, T., Osman, I., NUÑEZ, R. F., Macapinlac, H. A., Siedlecki, K. L., Verbel, D., Schwartz, L. B., Larson, S. M., & Scher, H. I. (2002) · Urology · doi:10.1016/s0090-4295(02)01509-1 · Cited by 194 · see citing works
Resistance of [ 18 F]-Fluorodeoxyglucose-Avid Metastatic Thyroid Cancer Lesions to Treatment with High-Dose Radioactive Iodine
Wang, W., Larson, S. M., Tuttle, R. M., Kalaigian, H., Kolbert, K. S., Sonenberg, M., & Robbins, R. J. (2001) · Thyroid · doi:10.1089/10507250152741028 · Cited by 179 · see citing works
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates
Dolfi, S. C., Chan, L. L., Qiu, J., Tedeschi, P. M., Bertino, J. R., Hirshfield, K. M., Oltvai, Z. N., & Vázquez, A. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-20 · Cited by 176 · see citing works
Anti-3-[ 18 F]FACBC Positron Emission Tomography-Computerized Tomography and 111 In-Capromab Pendetide Single Photon Emission Computerized Tomography-Computerized Tomography for Recurrent Prostate Carcinoma: Results of a Prospective Clinical Trial
Schuster, D. M., Nieh, P. T., Jani, A. B., Amzat, R., Bowman, F. D., HALKAR, R. K., Master, V. A., Nye, J. A., Odewole, O. A., Osunkoya, A. O., et al. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.10.065 · Cited by 172 · see citing works
Nitric Oxide-Mediated Regulation of Chemosensitivity in Cancer Cells
Matthews, N. E., Adams, M. A., Maxwell, L., Gofton, T. E., & Graham, C. H. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1879 · Cited by 167 · see citing works
PET imaging of cellular proliferation
Mankoff, D. A., Shields, A. F., & Krohn, K. A. (2005) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2004.09.005 · Cited by 161 · see citing works
Self-citation
Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer
Scher, B., Seitz, M., Albinger, W., et al. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0190-7 · Cited by 161 · see citing works
18F-FLT PET Does Not Discriminate Between Reactive and Metastatic Lymph Nodes in Primary Head and Neck Cancer Patients
Troost, E. G. C., Vogel, W. V., Merkx, M. A. W., et al. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037473 · Cited by 161 · see citing works
Imaging Cell Death
Neves, A., & Brindle, K. M. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.114264 · Cited by 158 · see citing works
18F-FLT PET/CT for Early Response Monitoring and Dose Escalation in Oropharyngeal Tumors
Troost, E. G. C., Bussink, J., Hoffmann, A. L., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069310 · Cited by 158 · see citing works
[18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung
Sohn, H.-J., Yang, Y.-J., Ryu, J., Oh, S. J., Im, K. C., Moon, D. H., Lee, K. H., Suh, C., Lee, J., & Kim, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0312 · Cited by 157 · see citing works
Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma
Herrmann, K., Wieder, H. A., Buck, A. K., Schöffel, M., Krause, B., Fend, F., Schuster, T., Büschenfelde, C. M. Z., Wester, H., Duyster, J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3025 · Cited by 153 · see citing works
Imaging hypoxia and angiogenesis in tumors
Rajendran, J. G., & Krohn, K. A. (2005) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2004.08.004 · Cited by 151 · see citing works
POSITRON EMISSION TOMOGRAPHY IN UROLOGICAL ONCOLOGY
Hoh, C. K., Seltzer, M., Franklin, J. R., deKernion, J. B., Phelps, M. E., & Belldegrun, A. S. (1998) · The Journal of Urology · doi:10.1016/s0022-5347(01)63916-8 · Cited by 147 · see citing works
[18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer
Minn, H. R. I., & Soini, I. (1989) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/bf00702620 · Cited by 143 · see citing works
18 F-labelled annexin V: a PET tracer for apoptosis imaging
Murakami, Y., Takamatsu, H., Taki, J., et al. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1378-8 · Cited by 141 · see citing works
Chemotherapy-Induced Apoptosis and Bcl-2 Levels Correlate with Breast Cancer Response to Chemotherapy
Buchholz, T. A., Davis, D. W., McConkey, D. J., Symmans, W. F., Valero, V., Jhingran, A., Tucker, S. L., Pusztai, L., Cristofanilli, M., Esteva, F. J., et al. (2003) · The Cancer Journal · doi:10.1097/00130404-200301000-00007 · Cited by 139 · see citing works
68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET
Ambrosini, V., Campana, D., Tomassetti, P., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1989-4 · Cited by 133 · see citing works
Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure
Demetri, G. D., Heinrich, M. C., Fletcher, J. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0482 · Cited by 133 · see citing works
Prospective Trial Incorporating Pre-/Mid-Treatment [18F]-Misonidazole Positron Emission Tomography for Head-and-Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy
Lee, N. Y., Nehmeh, S. A., Schöder, H. M., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.049 · Cited by 126 · see citing works
Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer
Sun, H., Sloan, A. E., Mangner, T. J., et al. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1713-8 · Cited by 118 · see citing works
Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors
Tian, M., Zhang, H., Oriuchi, N., Higuchi, T., & Endo, K. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1496-y · Cited by 116 · see citing works
Diagnostic Value of FDG PET and Salivary Gland Scintigraphy for Parotid Tumors
Uchida, Y., Minoshima, S., Kawata, T., et al. (2005) · Clinical Nuclear Medicine · doi:10.1097/00003072-200503000-00005 · Cited by 111 · see citing works
Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression
Contractor, K. B., Challapalli, A., Barwick, T. D., Winkler, M. H., Hellawell, G. O., Hazell, S., Tomasi, G., AL-NAHHAS, A. M., Mapelli, P., Kenny, L. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2048 · Cited by 111 · see citing works
PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer
Wieder, H. A., Geinitz, H., Rosenberg, R., Lordick, F., Becker, K., Stahl, A. R., Rummeny, E. J., Siewert, J. R., Schwaiger, M., & Stollfuß, J. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0292-2 · Cited by 110 · see citing works
Tumor Hypoxia Imaging
Sun, X., Niu, G., Chan, N., Shen, B., & Chen, X. S. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0420-z · Cited by 109 · see citing works
PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results.
Pauleit, D. O., Stoffels, G., Schaden, W., et al. (2005) · PubMed · Cited by 107 · see citing works
Radiolabeled choline as a proliferation marker: Comparison with radiolabeled acetate
Yoshimoto, M., Waki, A., Obata, A., Furukawa, T., Yonekura, Y., & Fujibayashi, Y. (2004) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2004.05.002 · Cited by 105 · see citing works
Imaging Cellular Proliferation During Chemo-Radiotherapy: A Pilot Study of Serial 18F-FLT Positron Emission Tomography/Computed Tomography Imaging for Non–Small-Cell Lung Cancer
Everitt, S., Hicks, R. J., Ball, D., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.12.039 · Cited by 100 · see citing works
Neuroimaging of juvenile pilocytic astrocytomas: an enigma.
FULHAM, M. J., Melisi, J. W., Nishimiya, J., et al. (1993) · Radiology · doi:10.1148/radiology.189.1.8372197 · Cited by 97 · see citing works
Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation
Barwick, T. D., Bencherif, B., Mountz, J. M., & Avril, N. E. (2009) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32832ee93b · Cited by 93 · see citing works
Early Detection of Erlotinib Treatment Response in NSCLC by 3′-Deoxy-3′-[18F]-Fluoro-L-Thymidine ([18F]FLT) Positron Emission Tomography (PET)
Ullrich, R. T., Zander, T., Neumaier, B., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003908 · Cited by 92 · see citing works
Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer
Cuaron, J. J., Dunphy, M. P., & Rimner, A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2012.00208 · Cited by 90 · see citing works
Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
Eubank, W. B., Mankoff, D. A., Schmiedl, U. P., et al. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.171.4.9763005 · Cited by 90 · see citing works
Self-citation
The impact of positron emission tomography (PET) on expected management during cancer treatment
Hillner, B. E., Siegel, B. A., Shields, A. F., Liu, D., Gareen, I. F., Hanna, L., Stine, S. H., & Coleman, R. E. (2008) · Cancer · doi:10.1002/cncr.24000 · Cited by 88 · see citing works
18F-ICMT-11, a Caspase-3–Specific PET Tracer for Apoptosis: Biodistribution and Radiation Dosimetry
Challapalli, A., Kenny, L. M., Hallett, W. A., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.118760 · Cited by 85 · see citing works
Assessment of Cellular Proliferation in Tumors by PET Using 18F-ISO-1
Dehdashti, F., Laforest, R. A., Gao, F., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111948 · Cited by 82 · see citing works
Prognostic Significance of 99mTc Hynic-rh-Annexin V Scintigraphy During Platinum-Based Chemotherapy in Advanced Lung Cancer
Kartachova, M. S., van Zandwijk, N., Burgers, S. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1337 · Cited by 82 · see citing works
An In vivo Tumor Model Exploiting Metabolic Response as a Biomarker for Targeted Drug Development
Cullinane, C. M., Dorow, D. S., Kansara, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2285 · Cited by 79 · see citing works
True tracers: comparing FDG with glucose and FLT with thymidine
Krohn, K. A., Mankoff, D. A., Muzi, M., et al. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.04.004 · Cited by 78 · see citing works
Self-citation
Role of 18F-Choline PET/CT in Biochemically Relapsed Prostate Cancer After Radical Prostatectomy
Marzola, M. C., Chondrogiannis, S., Ferretti, A., Grassetto, G., Rampin, L., Massaro, A., Castellucci, P., Picchio, M., AL-NAHHAS, A. M., Colletti, P. M., et al. (2012) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e318266cc38 · Cited by 77 · see citing works
Early identification of antigen-specific immune responses in vivo by [ 18 F]-labeled 3′-fluoro-3′-deoxy-thymidine ([ 18 F]FLT) PET imaging
Aarntzen, E. H. J. G., Srinivas, M., de Wilt, J. H. W., Jacobs, J. F. M., Lesterhuis, W. J., Windhorst, A. D., Troost, E. G. C., Bonenkamp, J. J., van Rossum, M. M., Blokx, W. A. M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113045108 · Cited by 77 · see citing works
Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models
Apisarnthanarax, S., Alauddin, M. M., Mourtada, F., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2720 · Cited by 75 · see citing works
The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer.
Katzenellenbogen, J. A., Welch, M. J., & Dehdashti, F. (1997) · PubMed · Cited by 73 · see citing works
18F-FACBC Compared With 11C-Choline PET/CT in Patients With Biochemical Relapse After Radical Prostatectomy: A Prospective Study in 28 Patients
Nanni, C., Schiavina, R., Brunocilla, E., Borghesi, M., Ambrosini, V., Zanoni, L., Gentile, G., Vagnoni, V., Romagnoli, D., Martorana, G. E., et al. (2013) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2013.08.002 · Cited by 72 · see citing works
The Role of Human Nucleoside Transporters in Uptake of 3′-Deoxy-3′-fluorothymidine
Paproski, R. J., Ng, A. M. L., Yao, S. Y. M., Graham, K., Young, J. D., & Cass, C. E. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.048900 · Cited by 71 · see citing works
18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer
Krause, B. J., Herrmann, K., Wieder, H. A., & Büschenfelde, C. M. Z. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057232 · Cited by 71 · see citing works
Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with 18F-ML-10
Allen, A. M., Ben-Ami, M., Reshef, A., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2150-8 · Cited by 71 · see citing works
Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors.
Kole, A. C., Nieweg, O., Hoekstra, H. J., et al. (1998) · PubMed · Cited by 71 · see citing works
Imaging of tumor glucose utilization with positron emission tomography
Bürkle, A., & Weber, W. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9151-x · Cited by 70 · see citing works
Probes for Non-invasive Matrix Metalloproteinase-targeted Imaging with PET and SPECT
Matusiak, N., van Waarde, A., Bischoff, R., et al. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319250011 · Cited by 70 · see citing works
The Role of 11C-Choline PET Imaging in the Early Detection of Recurrence in Surgically Treated Prostate Cancer Patients With Very Low PSA Level <0.5 ng/mL
Mamede, M. H., Ceci, F., Castellucci, P., et al. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31829af913 · Cited by 67 · see citing works
Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
Inoue, T., Kim, E. E., Wong, F. C., Yang, D. J., Bassa, P., Wong, W., Korkmaz, M., Tansey, W., Hicks, K., & Podoloff, D. A. (1996) · PubMed · Cited by 65 · see citing works
Multi-modality Imaging Identifies Key Times for Annexin V Imaging as an Early Predictor of Therapeutic Outcome
Mandl, S. J., Mari, C., Edinger, M., et al. (2004) · Molecular Imaging · doi:10.1162/153535004773861679 · Cited by 64 · see citing works
2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome.
Spence, A. M., Muzi, M., Graham, M. M., et al. (2002) · PubMed · Cited by 64 · see citing works
Imaging of Brain Tumors: Perfusion/Permeability
Thompson, G., Mills, S. J., Stivaros, S. M., et al. (2010) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2010.04.008 · Cited by 63 · see citing works
Initial Experience with the Radiotracer Anti-1-amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid (Anti-[18F]FACBC) with PET in Renal Carcinoma
Schuster, D. M., Nye, J. A., Nieh, P. T., Votaw, J. R., HALKAR, R. K., Issa, M. M., Yu, W., Sepulveda, J. N., Zeng, W., Young, A. N., et al. (2009) · Molecular Imaging and Biology · doi:10.1007/s11307-009-0220-5 · Cited by 59 · see citing works
The role of PET in monitoring therapy
Hicks, R. (2005) · Cancer Imaging · doi:10.1102/1470-7330.2005.0006 · Cited by 57 · see citing works
Discriminant Analysis of 18F-Fluorothymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma
Wardak, M., Schiepers, C. W., Dahlbom, M. L., Cloughesy, T. F., Chen, W., Satyamurthy, N., Czernin, J. G., Phelps, M. E., & Huang, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3290 · Cited by 56 · see citing works
Current and future uses of positron emission tomography in breast cancer imaging
Eubank, W. B., & Mankoff, D. A. (2004) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2004.03.007 · Cited by 55 · see citing works
Self-citation
Temporal and Spatial Evolution of Therapy-Induced Tumor Apoptosis Detected by Caspase-3–Selective Molecular Imaging
Nguyen, Q., Lavdas, I., Gubbins, J., Smith, G. S. T., Fortt, R. R., Carroll, L. S., Graham, M. A., & Aboagye, E. O. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3814 · Cited by 54 · see citing works
Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas.
Yamane, T., Daimaru, O., Ito, S., et al. (2004) · PubMed · Cited by 54 · see citing works
11C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy
Ceci, F., Castellucci, P., Mamede, M. H., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2272-z · Cited by 53 · see citing works
New targeted therapies in breast cancer
Kaklamani, V., & O’Regan, R. M. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.02.018 · Cited by 48 · see citing works
Biodistribution and Radiation Dosimetry of 18F-CP-18, a Potential Apoptosis Imaging Agent, as Determined from PET/CT Scans in Healthy Volunteers
Doss, M., Kolb, H. C., Walsh, J. C., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.119800 · Cited by 43 · see citing works
Monitoring Tumor Response to Therapy with 18F-FLT PET
Weber, W. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.071217 · Cited by 41 · see citing works
Impact of 18F-FDG PET Used After Initial Treatment of Cancer: Comparison of the National Oncologic PET Registry 2006 and 2009 Cohorts
Hillner, B. E., Siegel, B. A., Hanna, L., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.103911 · Cited by 38 · see citing works
FDG PET and PET/CT Imaging in Lymphoma and Melanoma
Macapinlac, H. A. (2004) · The Cancer Journal · doi:10.1097/00130404-200407000-00007 · Cited by 38 · see citing works
Evaluation of 2′-deoxy-2′-[18F]fluoro-5-methyl-1-β-l-arabinofuranosyluracil ([18F]-l-FMAU) as a PET imaging agent for cellular proliferation: comparison with [18F]-d-FMAU and [18F]FLT
Nishii, R., Volgin, A. Y., Mawlawi, O. R., et al. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0649-1 · Cited by 32 · see citing works
Diagnosis of maxillofacial tumor withl-3-[18F]-fluoro-α-methyltyrosine (FMT) PET: a comparative study with FDG-PET
Miyakubo, M., Oriuchi, N., Tsushima, Y., et al. (2007) · Annals of Nuclear Medicine · doi:10.1007/bf03033991 · Cited by 32 · see citing works
18F-FET PET/CT in Advanced Head and Neck Squamous Cell Carcinoma: an Intra-individual Comparison with 18F-FDG PET/CT
Haerle, S. K., Fischer, D. R., Schmid, D. T., et al. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0419-5 · Cited by 30 · see citing works
Prognostic value of 99mTc-HYNIC Annexin-V imaging in squamous cell carcinoma of the head and neck
Loose, D., Vermeersch, H., Vos, F. D., et al. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0577-0 · Cited by 30 · see citing works
Early Response Assessment in Gastrointestinal Stromal Tumors With FDG PET Scan 24 Hours After a Single Dose of Imatinib
Shinto, A., Nair, N., Dutt, A., et al. (2008) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31817792a3 · Cited by 28 · see citing works
Assessment of Therapy Response in Lung Cancer With 18F-α-Methyl Tyrosine PET
Kaira, K., Oriuchi, N., Yanagitani, N., Sunaga, N., Ishizuka, T., Mori, M., & Endo, K. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.09.4167 · Cited by 17 · see citing works
Monitoring Targeted Therapy: Is Fluorodeoxylucose Uptake a Marker of Early Response?
Linden, H. M., Krohn, K. A., Livingston, R. B., & Mankoff, D. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1152 · Cited by 13 · see citing works
Self-citation
Development of 18F-Labeled PET Probes for Imaging Cell Proliferation
Sai, K. K. S., Jones, L. A., & Mach, R. H. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313080003 · Cited by 11 · see citing works
ACRIN 6688 phase II study of fluorine-18 3′-deoxy-3′ fluorothymidine (FLT) in invasive breast cancer.
Jolles, P. R., Kostakoglu, L., Bear, H. D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.tps125 · Cited by 6 · see citing works
Imaging Studies in Anticancer Drug Development
Mankoff, D. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7358-0_11 · Cited by 5 · see citing works
Self-citation
PET Imaging of Brain Tumors
Langen, K., & Galldiks, N. (2013) · Medical radiology · doi:10.1007/174_2013_937 · Cited by 4 · see citing works

Flagged first, then by citations

Research works printed but not linked: 3

Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular pro- liferation. Radiol Clin North Am. 2005;43:153-167.
F]fluo- rothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol. 2000;27:143-156.
Sun X, Niu G, Chan N, Shen B, Chen X. Tumor hypoxia imag- ing. Mol Imaging Biol. 2011;13:399-410.

Sorted by citations

Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971 · see citing works
Mitochondria as biosynthetic factories for cancer proliferation
Ahn, C. S., & Metallo, C. M. (2015) · Cancer & Metabolism · doi:10.1186/s40170-015-0128-2 · Cited by 399 · see citing works
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272 · see citing works
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124 · see citing works
Glutathione-activated near-infrared II fluorescent probe for lung metastatic diagnosis and intraoperative imaging of tumor
Wang, Y., Zhao, G., Liu, Y., Wang, R., Xing, Y., Dou, K., & Yu, F. (2025) · Sensors and Actuators B: Chemical · doi:10.1016/j.snb.2024.137005 · Cited by 16 · see citing works

18F-microbubble for PET/US imaging: conception and in vivo imaging
Ariztia, J., Dauba, A., Novell, A., et al. (2022) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(22)00351-1
Focus on the Controversial Aspects of 64Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging
Colombié, M., Gouard, S., Frindel, M., Vidal, A., Chérel, M., Kraeber‐Bodéré, F., Rousseau, C., & Bourgeois, M. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00058 · Cited by 54 · see citing works
Radiosynthesis and in Vivo Imaging of Vegfr2 Pet Ligand [11c]BtfpPreprint
Kumar, D., Neelamegam, R., & Chaly, T. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4058983
TU‐E‐214‐03: Preclinical and Clinical Hypoxia Imaging: Current and Emerging Methods and Technology
Jeraj, R. (2011) · Medical Physics · doi:10.1118/1.3613201
Monitoring response to preventive therapy in patients with Huntington's disease (HD) using 18F-labeled fluorodeoxyglucose PET (FDG-PET) imaging
(2013) · Science-Business eXchange · doi:10.1038/scibx.2013.1045

Authors: Farwell, M. D., Pryma, D. A., & Mankoff, D. A.
Affiliations: Hospital of the University of Pennsylvania (US)
Corresponding author: Farwell, Michael D.
ORCID: Farwell, Michael D.
Pryma, Daniel A.
Mankoff, David A.
Venue: Cancer
Publisher: Wiley
Published: 2014-06-19
Volume: 120
Issue: 22
Pages: 3433-3445
ISSN: 0008-543X (ISSN-L)
1097-0142
DOI: 10.1002/cncr.28860
OpenAlex: W1585769594
Cited by: 230
References: 137
Citations by year: 2026: 4 · 2025: 26 · 2024: 17 · 2023: 19 · 2022: 23 · 2021: 22 · 2020: 24 · 2019: 21 · 2018: 23 · 2017: 22 · 2016: 14 · 2015: 13 · 2014: 1
FWCI: 2.59
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords: PET/CT, tumor imaging, 18F-fluorodeoxyglucose, FDG-PET, tumor hypoxia, apoptosis imaging
MeSH terms: Humans, Neoplasms, Prognosis, Tomography, X-Ray Computed, Dideoxynucleosides, Cell Hypoxia, Apoptosis, Fluorodeoxyglucose F18, Cell Proliferation, Positron-Emission Tomography, Multimodal Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PET/CT imaging in cancer: current applications and future directions

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks